|
1
|
Coughlin BA, Trombley BT and Mohr S:
Interleukin-6 (IL-6) mediates protection against glucose toxicity
in human Müller cells via activation of VEGF-A signaling. Biochem
Biophys Res Commun. 517:227–232. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Matthes AT, Manfroi B and Huard B:
Revisiting IL-6 antagonism in multiple myeloma. Crit Rev Oncol
Hematol. 105:1–4. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rizzo MD, Crawford RB, Bach A, Sermet S,
Amalfitano A and Kaminski NE: Imiquimod and interferon-alpha augment
monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a
human co-culture system. J Neuroimmunol. 333(576969)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Niu X, Chen Y, Qi L, Liang G, Wang Y,
Zhang L, Qu Y and Wang W: Hypoxia regulates angeogenic-osteogenic
coupling process via up-regulating IL-6 and IL-8 in human
osteoblastic cells through hypoxia-inducible factor-1α pathway.
Cytokine. 113:117–127. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kaur S, Bansal Y, Kumar R and Bansal G: A
panoramic review of IL-6: Structure, pathophysiological roles and
inhibitors. Bioorg Med Chem. 28(115327)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Choy E and Rose-John S: Interleukin-6 as a
multifunctional regulator: Inflammation, immune response, and
fibrosis. J Scleroderma Relat Disord. 2 (Suppl 2):S1–S5. 2017.
|
|
7
|
Scheller J, Chalaris A, Schmidt-Arras D
and Rose-John S: The pro- and anti-inflammatory properties of the
cytokine interleukin-6. Biochim Biophys Acta. 1813:878–888.
2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Prenissl N, Lokau J, Rose-John S, Haybaeck
J and Garbers C: Therapeutic blockade of the interleukin-6 receptor
(IL-6R) allows sIL-6R generation by proteolytic cleavage. Cytokine.
114:1–5. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Liang AP, Drazick AT, Gao H and Li Y:
Skeletal muscle secretion of IL-6 is muscle type specific: Ex vivo
evidence. Biochem Biophys Res Commun. 505:146–150. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Karthick SR, Sen RK, Gopinathan NR,
Dhillon MS, Nada R and Sharma RR: Can IL-6 predict the development
of fat embolism in polytrauma? A rabbit model pilot experimental
study. J Clin Orthop Trauma. 11 (Suppl 1):S86–S92. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Del Giudice M and Gangestad SW: Rethinking
IL-6 and CRP: Why they are more than inflammatory biomarkers, and
why it matters. Brain Behav Immun. 70:61–75. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bialuk I, Taranta A and Winnicka MM: IL-6
deficiency alters spatial memory in 4- and 24-month-old mice.
Neurobiol Learn Mem. 155:21–29. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhou E, Yan F, Li B, Chen M, Tu X, Wu S,
Wu H, Wei X, Fu S, Wu L, et al: Molecular and functional
characterization of IL-6 receptor (IL-6R) and glycoprotein 130
(gp130) in Nile tilapia (Oreochromis niloticus). Dev Comp Immunol.
106(103629)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ellingsgaard H, Hojman P and Pedersen BK:
Exercise and health-emerging roles of IL-6. Curr Opin Physiol.
10:49–54. 2019.
|
|
15
|
Unver N and McAllister F: IL-6 family
cytokines: Key inflammatory mediators as biomarkers and potential
therapeutic targets. Cytokine Growth Factor Rev. 41:10–17.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dittel LJ, Dittel BN and Brod SA: Ingested
ACTH blocks Th17 production by inhibiting GALT IL-6. J Neurol Sci.
409(116602)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gao S, Hu J, Wu X and Liang Z: PMA treated
THP-1-derived-IL-6 promotes EMT of SW48 through STAT3/ERK-dependent
activation of Wnt/β-catenin signaling pathway. Biomed Pharmacother.
108:618–624. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Santhosh Kumar S, Sajeli Begum A, Hira K,
Niazi S, Prashantha Kumar BR, Araya H and Fujimoto Y:
Structure-based design and synthesis of new 4-methylcoumarin-based
lignans as pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β)
inhibitors. Bioorg Chem. 89(102991)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tatu AL, Clatici VG and Nwabudike LC:
Rosacea-like demodicosis (but not primary demodicosis) and
papulopustular rosacea may be two phenotypes of the same disease-a
microbioma, therapeutic and diagnostic tools perspective. J Eur
Acad Dermatol Venereol. 33:e46–e47. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tatu AL, Ionescu MA and Nwabudike LC:
Contact allergy to topical mometasone furoate confirmed by
rechallenge and patch test. Am J Ther. 25:e497–e498.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Brănișteanu DE, Pintilie A, Dimitriu A,
Cerbu A, Ciobanu D, Oanţă A and Tatu AL: Clinical, laboratory and
therapeutic profile of lichen planus. Rev Med Chir Soc Med Nat.
121:25–32. 2017.
|
|
22
|
Stojanović-Radić Z, Pejčić M, Dimitrijević
M, Aleksić A, Anil Kumar NV, Salehi B, Cho CW and Sharifi-Rad J:
Piperine-a major principle of black pepper: A review of its
bioactivity and studies. Appl Sci. 9(4270)2019.
|
|
23
|
Mihăilă B, Dinică RM, Tatu AL and Buzia
OD: New insights in vitiligo treatments using bioactive compounds
from Piper nigrum. Exp Ther Med. 17:1039–1044. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tatu AL, Ciobotaru OR, Miulescu M, Buzia
OD, Elisei AM, Mardare N, Diaconu C, Robu S and Nwabudike LC:
Hydrochlorothiazide: Chemical structure, therapeutic, phototoxic
and carcinogenetic effects in dermatology. Rev Chim (Bucharest).
69:2110–2114. 2018.
|
|
25
|
Gerber PA, Buhren BA, Steinhoff M and
Homey B: Rosacea: The cytokine and chemokine network. J Investig
Dermatol Symp Proc. 15:40–47. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kim CH, Kim SW and Kim GS: Effects of
hydrochlorothiazide and furosemide diuretics on human bone marrow
stromal osteoprogenitor cells. Metabolism. 49:17–21.
2000.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yin M, Li G, Song H and Lin S: Identifying
the association between interleukin-6 and lichen planus: A
meta-analysis. Biomed Rep. 6:571–575. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nibali L, Fedele S, D'Aiuto F and Donos N:
Interleukin-6 in oral diseases: A review. Oral Dis. 18:236–243.
2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Singh S, Singh U and Pandey SS: Serum
concentration of IL-6, IL-2, TNF-α, and IFNγ in vitiligo patients.
Indian J Dermatol. 57:12–14. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lee HY, Stieger M, Yawalkar N and Kakeda
M: Cytokines and chemokines in irritant contact dermatitis.
Mediators Inflamm. 2013(916497)2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zeng W, Zhang Y, Duan F, Lin T, Liu X, Li
D and Wu K: Lipopolysaccharide enhances human herpesvirus 1
replication and IL-6 release in epithelial cells. Microb Pathog.
140(103961)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Farsakoglu Y, Palomino-Segura M, Latino I,
Zanaga S, Chatziandreou N, Pizzagalli DU, Rinaldi A, Bolis M,
Sallusto F, Stein JV and Gonzalez SF: Influenza vaccination induces
NK-cell-mediated type-II IFN response that regulates humoral
immunity in an IL-6-dependent manner. Cell Rep. 26:2307–2315.e5.
2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sun X, Tian Q, Wang L, Xue M and Zhong G:
IL-6-mediated signaling pathways limit chlamydia muridarum
infection and exacerbate its pathogenicity in the mouse genital
tract. Microbes Infect. 19:536–545. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Muhsin M, Ajendra J, Gentil K, Berbudi A,
Neumann AL, Klaas L, Schmidt KE, Hoerauf A and Hübner MP: IL-6 is
required for protective immune responses against early filarial
infection. Int J Parasitol. 48:925–935. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Stone SF, Price P, Keane NM, Murray RJ and
French MA: Levels of IL-6 and soluble IL-6 receptor are increased
in HIV patients with a history of immune restoration disease after
HAART. HIV Med. 3:21–27. 2002.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Modrigan M, Draganescu M, Condratovici CP,
Pavel LL and Condratovici AP: Clinical personality patterns in
young adults with HIV nosocomial infection from the region of
southeast Romania. Mater Plast. 54:175–179. 2017.
|
|
37
|
Tiutiuca C, Drăgănescu M, Iancu AV,
Chesaru BI, Arbune M, Maftei N and Popescu E: Resistence profile of
the isolated bacterial stems in invasive infections in three
hospitals from the south-east of Romania. Rev Chim (Bucharest).
68:1122–1125. 2017.
|
|
38
|
Saiki P, Nakajima Y, Van Griensven LJLD
and Miyazaki K: Real-time monitoring of IL-6 and IL-10 reporter
expression for anti-inflammation activity in live RAW 264.7 cells.
Biochem Biophys Res Commun. 505:885–890. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Shirakura K, Ishiba R, Kashio T, Sakai M,
Fukushima Y, Yamamoto N, Manabe S, Shigesada N, Tanaka T, Hino N,
et al: Endothelial Robo4 regulates IL-6 production by endothelial
cells and monocytes via a crosstalk mechanism in inflammation.
Biochem Biophys Res Commun. 495:801–806. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Uchibori T, Matsuda K, Shimodaira T,
Sugano M, Uehara T and Honda T: IL-6 trans-signaling is another
pathway to upregulate osteopontin. Cytokine. 90:88–95.
2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Atzeni F, Nucera V, Masala IF,
Sarzi-Puttini P and Bonitta G: Il-6 involvement in pain, fatigue
and mood disorders in rheumatoid arthritis and the effects of Il-6
inhibitor sarilumab. Pharmacol Res. 149(104402)2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Gao ST, Xu T, Xun CH, Liang WD, Cao R, Mao
C and Sheng WB: Significant association of IL-6-572G/C,
IL-6-597G/A, and IL-6-174G/C polymorphisms and susceptibility to
lumbar degenerative disease: A meta-analysis. Clin Neurol
Neurosurg. 175:40–46. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Van Gaal LF, Mertens IL and De Block CE:
Mechanisms linking obesity with cardiovascular disease. Nature.
444:875–880. 2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Eder K, Baffy N, Falus A and Fulop AK: The
major inflammatory mediator interleukin-6 and obesity. Inflamm Res.
58:727–736. 2009.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Libby P: Inflammation in atherosclerosis.
Arterioscler Thromb Vasc Biol. 32:2045–2051. 2012.PubMed/NCBI View Article : Google Scholar
|
|
46
|
IL6R Genetics Consortium Emerging Risk
Factors Collaboration. Sarwar N, Butterworth AS, Freitag DF,
Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, et
al: Interleukin-6 receptor pathways in coronary heart disease: A
collaborative meta-analysis of 82 studies. Lancet. 379:1205–1213.
2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Interleukin-6 Receptor Mendelian
Randomisation Analysis (IL6R MR) Consortium. Swerdlow DI, Holmes
MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C,
Peasey A, et al: The interleukin-6 receptor as a target for
prevention of coronary heart disease: A mendelian randomisation
analysis. Lancet. 379:1214–1224. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Fernandez-Real JM, Vayreda M, Richart C,
Gutierrez C, Broch M, Vendrell J and Ricart W: Circulating
interleukin 6 levels, blood pressure, and insulin sensitivity in
apparently healthy men and women. J Clin Endocrinol Metab.
86:1154–1159. 2001.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Emerging Risk Factors Collaboration.
Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG,
Collins R and Danesh J: C-reactive protein concentration and risk
of coronary heart disease, stroke, and mortality: An individual
participant meta-analysis. Lancet. 375:132–140. 2010.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Hartman J and Frishman WH: Inflammation
and atherosclerosis: A review of the role of interleukin-6 in the
development of atherosclerosis and the potential for targeted drug
therapy. Cardiol Rev. 22:147–151. 2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Luc G, Bard JM, Juhan-Vague I, Ferrieres
J, Evans A, Amouyel P, Arveiler D, Fruchart JC and Ducimetiere P:
PRIME Study Group. C-reactive protein, interleukin-6, and
fibrinogen as predictors of coronary heart disease: The PRIME
study. Arterioscler Thromb Vasc Biol. 23:1255–1261. 2003.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Shlipak MG, Ix JH, Bibbins-Domingo K, Lin
F and Whooley MA: Biomarkers to predict recurrent cardiovascular
disease: The heart and soul study. Am J Med. 121:50–57.
2008.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Lee JK, Bettencourt R, Brenner D, Le TA,
Barrett-Connor E and Loomba R: Association between serum
interleukin-6 concentrations and mortality in older adults: The
Rancho Bernardo study. PLoS One. 7:1–7. 2012.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Scharnagl H, Stojakovic T, Weihrauch G,
Winkelmann BR, Boehm BO and März W: Interleukin-6 is stronger
associated with all-cause and cardiovascular mortality than
C-reactive protein, serum amyloid and fibrinogen (the luric study).
Atheroscler Suppl. 11(42)2010.
|
|
55
|
Fan ZX, Hua Q, Li YP, Liu RK and Yang Z:
Interleukin-6, but not soluble adhesion molecules, predicts a
subsequent mortality from cardiovascular disease in patients with
acute ST-segment elevation myocardial infarction. Cell Biochem
Biophys. 61:443–448. 2011.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Zakynthinos E and Pappa N: Inflammatory
biomarkers in coronary artery disease. J Cardiol. 53:317–333.
2009.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Yudkin JS, Kumari M, Humphries SE and
Mohamed-Ali V: Inflammation, obesity, stress and coronary heart
disease: Is interleukin-6 the link? Atherosclerosis. 148:209–214.
2000.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Fontes JA, Rose NR and Čiháková D: The
varying faces of IL-6: From cardiac protection to cardiac failure.
Cytokine. 74:62–68. 2015.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Baune BT, Rothermundt M, Ladwig KH,
Meisinger C and Berger K: Systemic inflammation (interleukin 6)
predicts all cause mortality in men: Results from a 9-year
follow-up of the MEMO study. Age (Dordr). 33:209–217.
2011.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Fisman EZ, Benderly M, Esper RJ, Behar S,
Boyko V, Adler Y, Tanne D, Matas Z and Tenenbaum A: Interleukin-6
and the risk of future cardiovascular events in patients with
angina pectoris and/or healed myocardial infarction. Am J Cardiol.
98:14–18. 2006.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Boekholdt SM and Stroes ES: The
interleukin-6 pathway and atherosclerosis. Lancet. 379:1176–1178.
2012.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Mendoza CE, Rosado MF and Bernal L: The
role of interleukin-6 in cases of cardiac myxoma. Clinical
features, immunologic abnormalities, and a possible role in
recurrence. Tex Heart Inst J. 28:3–7. 2001.PubMed/NCBI
|
|
63
|
Chae CU, Lee RT, Rifai N and Ridker PM:
Blood pressure and inflammation in apparently healthy men.
Hypertension. 38:399–403. 2001.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Danesh J, Kaptoge S, Mann AG, Sarwar N,
Wood A, Angleman SB, Wensley F, Higgins JPT, Lennon L, Eiriksdottir
G, et al: Long-term interleukin-6 levels and subsequent risk of
coronary heart disease: Two new prospective studies and a
systematic review. PLoS Med. 5(e78)2008.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Volpato S, Guralnik JM, Ferrucci L,
Balfour J, Chaves P, Fried LP and Harris TB: Cardiovascular
disease, interleukin-6, and risk of mortality in older women: The
women's health and aging study. Circulation. 103:947–953.
2001.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Rao M, Guo D, Perianayagam MC, Tighiouart
H, Jaber BL, Pereira BJ and Balakrishnan VS: Plasma interleukin-6
predicts cardiovascular mortality in hemodialysis patients. Am J
Kidney Dis. 45:324–333. 2005.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Haugen E, Gan LM, Isic A, Skommevik T and
Fu M: Increased interleukin-6 but not tumour necrosis factor-alpha
predicts mortality in the population of elderly heart failure
patients. Exp Clin Cardiol. 13:19–24. 2008.PubMed/NCBI
|
|
68
|
Panichi V, Maggiore U, Taccola D, Migliori
M, Rizza GM, Consani C, Bertini A, Sposini S, Perez-Garcia R, Rindi
P, et al: Interleukin-6 is a stronger predictor of total and
cardiovascular mortality than C-reactive protein in haemodialysis
patients. Nephrol Dial Transplant. 19:1154–1160. 2004.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Candore G, Balistreri CR, Listì F,
Grimaldi MP, Vasto S, Colonna-Romano G, Franceschi C, Lio D,
Caselli G and Caruso C: Immunogenetics, gender, and longevity. Ann
NY Acad Sci. 1089:516–537. 2006.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Frangogiannis NG: The inflammatory
response in myocardial injury, repair, and remodelling. Nat Rev
Cardiol. 11:255–265. 2014.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Groot HE, Al Ali L, van der Horst IC,
Schurer RA, van der Werf HW, Lipsic E, van Veldhuisen DJ, Karper JC
and van der Harst P: Plasma interleukin 6 levels are associated
with cardiac function after ST-elevation myocardial infarction.
Clin Res Cardiol. 108:612–621. 2019.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Empana JP, Jouven X, Canoui-Poitrine F,
Luc G, Tafflet M, Haas B, Arveiler D, Ferrieres J, Ruidavets JB,
Montaye M, et al: C-reactive protein, interleukin 6, fibrinogen and
risk of sudden death in European middle-aged men: The PRIME study.
Arterioscler Thromb Vasc Biol. 30:2047–2052. 2010.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Samanta A, Cheng G, Davani A, Girgis M,
Chen L, Choksi K, Zhao L, Vincent RJ, Hauptman J and Dawn B:
Genetic deletion of interleukin-6 attenuates left ventricular
dysfunction and remodeling after a reperfused myocardial
infarction. Circulation. 130 (Suppl 2)(A15693)2014.
|
|
74
|
Luna JM, Moon YP, Liu KM, Spitalnik S,
Paik MC, Cheung K, Sacco RL and Elkind MS: High-sensitivity
C-reactive protein and interleukin-6-dominant inflammation and
ischemic stroke risk: The northern Manhattan study. Stroke.
45:979–987. 2014.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Bacchiega BC, Bacchiega AB, Usnayo MJ,
Bedirian R, Singh G and Pinheiro GD: Interleukin 6 inhibition and
coronary artery disease in a high risk population: A prospective
community based clinical study. J Am Heart Assoc.
6(e005038)2017.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Tousoulis D, Oikonomou E, Economou EK,
Crea F and Kaski JC: Inflammatory cytokines in atherosclerosis:
Current therapeutic approaches. Eur Heart J. 37:1723–1732.
2016.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Welsh P, Grassia G, Botha S, Sattar N and
Maffia P: Targeting inflammation to reduce cardiovascular disease
risk: A realistic clinical prospect? Br J Pharmacol. 174:3898–3913.
2017.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Jones G, Sebba A, Gu J, Lowenstein MB,
Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T
and Genovese MC: Comparison of tocilizumab monotherapy versus
methotrexate monotherapy in patients with moderate to severe
rheumatoid arthritis: The Ambition study. Ann Rheum Dis. 69:88–96.
2010.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Smolen JS, Beaulieu A, Rubbert-Roth A,
Ramos-Remus C, Rovensky J, Alecock E, Woodworth T and Alten R:
OPTION Investigators. Effect of interleukin-6 receptor inhibition
with tocilizumab in patients with rheumatoid arthritis (OPTION
study): A double-blind, placebo-controlled, randomized trial.
Lancet. 371:987–997. 2008.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Gabay C, McInnes IB, Kavanaugh A, Tuckwell
K, Klearman M, Pulley J and Sattar N: Comparison of lipid and
lipid-associated cardiovascular risk marker changes after treatment
with tocilizumab or adalimumab in patients with rheumatoid
arthritis. Ann Rheum Dis. 75:1806–1812. 2016.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Gabay C, Emery P, van Vollenhoven R,
Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal
S, Green J, et al: Tocilizumab monotherapy versus adalimumab
monotherapy for treatment of rheumatoid arthritis (ADACTA): A
randomised, double-blind, controlled phase 4 trial. Lancet.
381:1541–1550. 2013.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Yokoe I, Kobayashi H, Nishiwaki A,
Sugiyama K, Nagasawa Y, Karasawa H, Iwata M, Nozaki T, Ikumi N,
Inomata H, et al: FRI0204 effect of tocilizumab treatment on QTc
interval in patients with rheumatoid arthritis without cardiac
symptoms. Ann Rheum Dis. 75 (Suppl 2):S505.1–505. 2016.
|
|
83
|
Kobayashi H, Yokoe I, Nishiwaki A, Sato H
and Kobayashi Y: OP0313 effect of tocilizumab on left ventricular
function assessed using a comprehensive cardiac magnetic resonance
approach in rheumatoid arthritis patients without cardiac symptoms.
Ann Rheum Dis. 72 (Suppl 3)(A160)2014.
|
|
84
|
Dello SA, Bloemen JG, van de Poll MC, van
Dam RM, Stoot JHMB, van den Broek MAJ, Buurman WA, Bemelmans MHA,
Olde Damink SWM and Dejong CHC: Gut and liver handling of
interleukin-6 during liver resection in man. HPB (Oxford).
13:324–331. 2011.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Kornasiewicz O, Grąt M, Dudek K,
Lewandowski Z, Gorski Z, Zieniewicz K and Krawczyk M: Serum levels
of HGF, IL-6, and TGF-α after benign liver tumor resection. Adv Med
Sci. 60:173–177. 2015.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Fang C, Cai X, Hayashi S, Hao S, Sakiyama
H, Wang X, Yang Q, Akira S, Nishiguchi S, Fujiwara N, et al:
Caffeine-stimulated muscle IL-6 mediates alleviation of
non-alcoholic fatty liver disease. Biochim Biophys Acta Mol Cell
Biol Lipids. 1864:271–280. 2019.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Rollwagen FM, Davis TA, Li YY, Pacheco ND
and Zhu XL: Orally administered IL-6 induces elevated intestinal
GM-CSF gene expression and splenic CFU-GM. Cytokine. 27:107–112.
2004.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Grivennikov S, Karin E, Terzic J, Mucida
D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H,
Eckmann L and Karin M: IL-6 and Stat3 are required for survival of
intestinal epithelial cells and development of colitis-associated
cancer. Cancer Cell. 15:103–113. 2009.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Waldner MJ and Neurath MF: Master
regulator of intestinal disease: IL-6 in chronic inflammation and
cancer development. Semin Immunol. 26:75–79. 2014.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Comen EA, Bowman RL and Kleppe M:
Underlying causes and therapeutic targeting of the inflammatory
tumor microenvironment. Front Cell Dev Biol. 6(56)2018.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Allen TL, Whitham M and Febbraio MA: IL-6
muscles in on the gut and pancreas to enhance insulin secretion.
Cell Metab. 15:8–9. 2012.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Ramis IB, Vianna JS, Gonçalves CV, von
Groll A, Dellagostin OA and da Silva PEA: Polymorphisms of the
IL-6, IL-8 and IL-10 genes and the risk of gastric pathology in
patients infected with Helicobacter pylori. J Microbiol
Immunol Infect. 50:153–159. 2017.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Lang Lehrskov L, Lyngbaek MP, Soederlund
L, Legaard GE, Ehses JA, Heywood SE, Wewer Albrechtsen NJ, Holst
JJ, Karstoft K, Pedersen BK and Ellingsgaard H: Interleukin-6
delays gastric emptying in humans with direct effects on glycemic
control. Cell Metab. 27:1201–1211.e3. 2018.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Fan K, Yang C, Fan Z, Huang Q, Zhang Y,
Cheng H, Jin K, Lu Y, Wang Z, Luo G, et al: MUC16 C
terminal-induced secretion of tumor-derived IL-6 contributes to
tumor-associated Treg enrichment in pancreatic cancer. Cancer Lett.
418:167–175. 2018.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Hsieh CL, Liu SJ, Shen CR, Chen MY, Hsu
SC, Tsai JP, Li YS, Yang CJ, Chong P and Chen HW: IL-6-transfected
tumor cells modulate the status of CD8(+) and CD4(+) T cells to
control tumor growth. Immunobiology. 215:486–491. 2010.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Zhang LJ, Liu W, Gao YM, Qin YJ and Wu RD:
The expression of IL-6 and STAT3 might predict progression and
unfavorable prognosis in Wilms' tumor. Biochem Biophys Res Commun.
435:408–413. 2013.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Wang S, Li L, Zhou Y, He Y, Wei Y and Tao
A: Heterotypic cell-in-cell structures in colon cancer can be
regulated by IL-6 and lead to tumor immune escape. Exp Cell Res.
382(111447)2019.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Jiang J, Wang GZ, Wang Y, Huang HZ, Li WT
and Qu XD: Hypoxia-induced HMGB1 expression of HCC promotes tumor
invasiveness and metastasis via regulating macrophage-derived IL-6.
Exp Cell Res. 367:81–88. 2018.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Fisher DT, Appenheimer MM and Evans SS:
The two faces of IL-6 in the tumor microenvironment. Semin Immunol.
26:38–47. 2014.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Zhao M: Cytokine storm and
immunomodulatory therapy in COVID-19: Role of chloroquine and
anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents.
55(105982)2020.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Azzi L, Carcano G, Gianfagna F, Grossi P,
Gasperina DD, Genoni A, Fasano M, Sessa F, Tettamanti L, Carinci F,
et al: Saliva is a reliable tool to detect SARS-CoV-2. J Infect.
81:e45–e50. 2020.PubMed/NCBI View Article : Google Scholar
|
|
102
|
World Health Organization-Coronavirus
disease (COVID-2019) situation reports. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200421-sitrep-92-covid-19.pdf?sfvrsn=38e6b06d_6.
Accessed April 23, 2020.
|
|
103
|
Luo P, Liu Y, Qiu L, Liu X, Liu D and Li
J: Tocilizumab treatment in COVID-19: A single center experience. J
Med Virol. 92:814–818. 2020.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Zhang C, Wu Z, Li JW, Zhao H and Wang GQ:
The cytokine release syndrome (CRS) of severe COVID-19 and
Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the
key to reduce the mortality. Int J Antimicrob Agents.
55(105954)2020.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Liu B, Li M, Zhou Z, Guan X and Xiang Y:
Can we use interleukin-6 (IL-6) blockade for coronavirus disease
2019 (COVID-19)-induced cytokine release syndrome (CRS)? J
Autoimmun. 111(102452)2020.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Smolen JS, Aletaha D, Choy EH, Jones SA,
Takeuchi T and McInnes I: Targeting IL-6: A review of data.
Considerations Med. 2:12–18. 2018.
|
|
107
|
Valle ML, Dworshak J, Sharma A, Ibrahim
AS, Al-Shabrawey M and Sharma S: Inhibition of interleukin-6
trans-signaling prevents inflammation and endothelial barrier
disruption in retinal endothelial cells. Exp Eye Res. 178:27–36.
2019.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Huizinga TW, Fleischmann RM, Jasson M,
Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl
N and Genovese MC: Sarilumab, a fully human monoclonal antibody
against IL-6Rα in patients with rheumatoid arthritis and an
inadequate response to methotrexate: Efficacy and safety results
from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis.
73:1626–1634. 2014.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Tanaka Y and Mola EM: IL-6 targeting
compared to TNF targeting in rheumatoid arthritis: Studies of
olokizumab, sarilumab and sirukumab. Ann Rheum Dis. 73:1595–1597.
2014.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Kretsos K, Golor G, Jullion A, Hickling M,
McCabe S, Shaw S, Jose J and Oliver R: Safety and pharmacokinetics
of olokizumab, an anti-IL-6 monoclonal antibody, administered to
healthy male volunteers: A randomized phase I study. Clin Pharmacol
Drug Dev. 3:388–395. 2014.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Docea AO, Tsatsakis A, Albulescu D,
Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou
M, Drakoulis N, et al: A new threat from an old enemy: Re-emergence
of coronavirus (Review). Int J Mol Med. 45:1631–1643.
2020.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Calina D, Docea AO, Petrakis D, Egorov AM,
Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F,
Vinceti M, et al: Towards effective COVID-19 vaccines: Updates,
perspectives and challenges (Review). Int J Mol Med. 46:3–16.
2020.PubMed/NCBI View Article : Google Scholar
|
